Anúncio
relacionado a: Memorial Sloan-Kettering Cancer CenterOver 135 Years of Exceptional Care. Receive World-Class Cancer Treatment at MSK. Memorial Sloan Kettering specializes in More Than 400 Types of Cancer, Including Yours.
- Locations
View Our Locations Today.-Safe &
Secure Marketplace!
- Find a Location
Our Expert Care. Closer to You.
Find a MSK Location Near You.
- Donate
Memorial Sloan Kettering Cancer
Center-Don't miss out on donations.
- Donate to MSK
Drive Research and Treatment.
Support Lifesaving Work.
- Cancer Clinical Trials
Learn More About Clinical Trials
at Memorial Sloan Kettering.
- Request an Appointment
Make an appointment today
Speak to an MSK cancer expert
- Locations
Resultado da Busca
At MSK, cancer care – from immunotherapy and surgery to integrative medicine – is the only thing we do. Call us at 833-461-0165, visit us online at MSKCC.org, or in person at 1275 York Avenue, New York, NY, or at our other locations in New York City, Long Island, Westchester, and New Jersey.
Learn about MSK's vision, mission, and core values, and how they guide its work to end cancer for life. MSK is a leading comprehensive cancer center that provides personalized, compassionate, expert care and conducts innovative research and education.
Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a cancer treatment and research institution in Manhattan in New York City. It was founded in 1884 as the New York Cancer Hospital. MSKCC is one of 72 National Cancer Institute-designated Comprehensive Cancer Centers.
IMPLICATIONS FOR PRACTICE: Identification of fibroblast growth factor receptor (FGFR) aberrations in cholangiocarcinoma and bladder cancer led to development of selective FGFR inhibitors for these indications, based on clinical benefit and safety profiles.
- Mario E Lacouture, Vincent Sibaud, Milan J Anadkat, Benjamin Kaffenberger, Jonathan Leventhal, Kathl...
- 2021
15 de fev. de 2022 · The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes.
23 de jan. de 2024 · Abstract. Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML).
